Curium Gains FDA Approval for BEXLUTRY in GEP-NETs
BOSTON, Mass. — September 14, 2026 Curium™ announced that the U.S. Food and Drug Administration (FDA) has approved its...
Curium
Advertisement
Curium to Merge with Lantheus in $8B Radiopharma Deal
Boston & Bedford, Massachusetts, August 3, 2026 Curium and Lantheus Holdings, Inc. have entered into a definitive merger agreement...
Haemonetics Study Validates VASCADE MVP XL Performance
Boston, Massachusetts, August 3, 2026 Haemonetics Corporation has announced the publication of a major real-world clinical study providing additional...
Teva Highlights Long-Term AUSTEDO Success in Tardive Dyskinesia Care
PARSIPPANY, N.J. and TEL AVIV, Israel, June 20, 2026 Teva Pharmaceutical Industries Ltd. has unveiled compelling new long-term data...
Curium Court Victory Clears Path for U.S. GEP-NET Therapy
BOSTON, MA, June 18, 2026 Curium™ has secured a significant legal and commercial milestone after prevailing in a patent...
Advertisements
Haisco and Lilly Forge $3B Deal to Advance New Medicines
SILICON VALLEY, Calif. & BEIJING, June 1, 2026 Haisco Pharmaceutical Group Co., Ltd. has announced a landmark licensing and...
Curium Invests €32M to Expand Prostate Cancer RLT Production
PARIS, France, June 1, 2026 Curium, a global leader in radiopharmaceuticals and nuclear medicine, has announced a strategic investment...
Advertisement
